Hansa Biopharma AB (OSTO:HNSA)
kr 42.46 0.62 (1.48%) Market Cap: 2.78 Bil Enterprise Value: 3.18 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 73/100

Half Year 2020 Hansa Biopharma AB Earnings Call Transcript

Jul 16, 2020 / 12:00PM GMT
Release Date Price: kr252 (-2.55%)
Operator

Ladies and gentlemen, welcome to the Hansa Biopharma AB Interim Report for January to June 2020. (Operator Instructions) Today, I'm pleased to present CEO, Søren Tulstrup. Speaker, please begin.

SÃ;ren Tulstrup;publ;President;CEO
Hansa Biopharma AB

¸ - ()-&

Thank you, operator. Good afternoon to those of you in Europe, and good morning to those in the U.S. Welcome to the Hansa Biopharma conference call to discuss the results for the first half of the year of 2020. I'm Søren Tulstrup, CEO of Hansa Biopharma. With me today, I have our CFO, Donato Spota; as well as our Head of Investor Relations, Klaus Sindahl. Today, we'll review the overall progress and highlights of the business as well as near-term milestones. Our presentation should take 15 minutes. And after that, we'll take your questions.

Now please turn to Slide 2. Please allow me to draw your attention to our forward-looking statements, which apply to this presentation.

Please turn to Slide 3. Hansa Biopharma's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot